Alterity Therapeutics (PRNAD) Net Income towards Common Stockholders (2009 - 2019)

Alterity Therapeutics (PRNAD) has reported Net Income towards Common Stockholders for 9 consecutive years, with $87328.6 the latest figure, recorded in Q4 2019.

• In Q4 2019, Net Income towards Common Stockholders rose 12295851.38% year-over-year to $87328.6; the TTM figure through Jun 2021 stood at $87328.6 (up 100.08% YoY), while the FY2025 annual figure was -$7.8 million, up 100.0% from the prior year.
• Net Income towards Common Stockholders came in at $87328.6 for Q4 2019 at Alterity Therapeutics, up from -$109.7 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $87328.6 in Q4 2019, with the low at -$109.7 million in Q2 2019.
• Average Net Income towards Common Stockholders over 4 years is -$54.9 million, with a median of -$55.5 million recorded in 2016.
• The largest YoY upside for Net Income towards Common Stockholders was 12295851.38% in 2019 against a maximum downside of 0.71% in 2019.
• Year by year, Net Income towards Common Stockholders stood at -$2.7 million in 2016, then surged by 100.0% to $0.52 in 2017, then soared by 35.81% to $0.71 in 2018, then soared by 12295851.38% to $87328.6 in 2019.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $87328.6, -$109.7 million, and $0.71 for Q4 2019, Q2 2019, and Q4 2018 respectively.